| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Neurological and Psychiatric Sciences,*University of Padova, Padova, Italy, and the Institute of Anatomy,University of Ljubljana, Ljubljana, Slovenia
The diagnosis of limb girdle muscular dystrophy (LGMD) type 2A (due to mutations in the gene encoding for calpain-3) is currently based on protein analysis, but mutant patients with normal protein expression have also been identified. In this study we investigated 150 LGMD patients with normal calpain-3 protein expression, identified gene mutations by an allele-specific polymerase chain reaction test, and analyzed the mutant calpain-3 catalytic activity. Four different mutations were found in eight patients (5.5%): a frame-shifting deletion (550 A del) and three missense (R490Q, R489Q, R490W). Patients with normal calpain-3 protein expression on Western blot are a considerable proportion (20%) of our total LGMD2A population. While in control muscle the calpain-3 Ca++-dependent autocatalytic activity was evident within 5 minutes and was prevented by ethylene diaminetetraacetic acid, in all mutant patient samples the protein was not degraded, indicating that the normal autocatalytic function had been lost. By this new functional test, we show that conventional protein diagnosis fails to detect some mutant proteins, and prove the pathogenetic role of R490Q, R489Q, R490W missense mutations. We suggest that these mutations impair protein activity by affecting interdomain protein interaction, or reduce autocatalytic activity by lowering the Ca++ sensitivity.
This article has been cited by other articles:
 |
|
 |
|
  E. J. Groen, R. Charlton, R. Barresi, L. V. Anderson, M. Eagle, J. Hudson, M. S. Koref, V. Straub, and K. M. D. Bushby Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A Brain, December 1, 2007; 130(12): 3237 - 3249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Fanin, L Nardetto, A C Nascimbeni, E Tasca, M Spinazzi, R Padoan, and C Angelini Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A J. Med. Genet., October 1, 2007; 44(10): 609 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Murphy, C. A. Goodman, M. J. McKenna, J. Bennie, M. Leikis, and G. D. Lamb Calpain-3 is autolyzed and hence activated in human skeletal muscle 24 h following a single bout of eccentric exercise J Appl Physiol, September 1, 2007; 103(3): 926 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Fanin, A C Nascimbeni, and C Angelini Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations J. Med. Genet., January 1, 2007; 44(1): 38 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kramerova, E. Kudryashova, B. Wu, and M. J. Spencer Regulation of the M-Cadherin-{beta}-Catenin Complex by Calpain 3 during Terminal Stages of Myogenic Differentiation Mol. Cell. Biol., November 15, 2006; 26(22): 8437 - 8447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fanin, A. C. Nascimbeni, L. Fulizio, M. Spinazzi, P. Melacini, and C. Angelini Generalized Lysosome-Associated Membrane Protein-2 Defect Explains Multisystem Clinical Involvement and Allows Leukocyte Diagnostic Screening in Danon Disease Am. J. Pathol., April 1, 2006; 168(4): 1309 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Saenz, F. Leturcq, A. M. Cobo, J. J. Poza, X. Ferrer, D. Otaegui, P. Camano, M. Urtasun, J. Vilchez, E. Gutierrez-Rivas, et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene Brain, April 1, 2005; 128(4): 732 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kramerova, E. Kudryashova, J.G. Tidball, and M. J. Spencer Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro Hum. Mol. Genet., July 1, 2004; 13(13): 1373 - 1388. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
